Wanyong Lian - Sinopharm Group Supervisor
Executive
Mr. Lian Wanyong is NonExecutive Director of Sinopharm Group Co., Ltd. He joined the Company on 22 December 2008 as a nonexecutive Director and had been a Supervisor since 7 January 2011. He has over 16 years of working experience, all of which is management experience. Mr. Lian obtained a bachelors degree in medicine, majoring in clinical medicine, from Hunan University of Medicine in July 1993, a masters degree in medicine, majoring in pharmacology, from Zhongshan Medicine University in July 1996 and a masters degree in business administration from the University of Miami in May 2002. Mr. Lian was previously the manager of the operation and audit department of China National Group Corporationration of Traditional Herbal Medicine and a deputy head of the financial assets management department of CNPGC from January 2004 to June 2005 and from June 2005 to February 2008, respectively. Mr. Lian was the head of the investment management department of CNPGC since February 2008. since 2016.
| Age | 52 |
| Tenure | 9 years |
| Phone | 86 21 2305 2666 |
| Web | https://www.sinopharmgroup.com.cn |
Sinopharm Group Management Efficiency
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.Sinopharm Group Co has accumulated 8.42 B in total debt with debt to equity ratio (D/E) of 0.89, which is about average as compared to similar companies. Sinopharm Group has a current ratio of 1.28, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sinopharm Group until it has trouble settling it off, either with new capital or with free cash flow. So, Sinopharm Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinopharm Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinopharm to invest in growth at high rates of return. When we think about Sinopharm Group's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | EXECUTIVE Age | ||
| Ma Xiaoqin | Akso Health Group | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 |
Sinopharm Group Leadership Team
Elected by the shareholders, the Sinopharm Group's board of directors comprises two types of representatives: Sinopharm Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinopharm. The board's role is to monitor Sinopharm Group's management team and ensure that shareholders' interests are well served. Sinopharm Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinopharm Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yijian Wu, Non-Executive Director | ||
| Xiaojuan Li, Chief Officer | ||
| Qingming Yu, Executive Director | ||
| Yong Liu, Chief Legal Advisor and VP | ||
| Shuangjun Xu, Vice President | ||
| Xiuchang Jiang, CFO VP | ||
| Wanyong Lian, Supervisor | ||
| Maisong Cai, Vice President |
Sinopharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sinopharm Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |